Loading clinical trials...
Loading clinical trials...
A Phase 2A, Placebo-controlled, Randomized, Dose Response Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C Spirulina GEBT in Patients With Moderate to Severe Gastroparesis
Conditions
Interventions
PCS12852
Placebo
Locations
9
United States
Torrance Clinical Research Institute, Inc.
Lomita, California, United States
TriWest Research Associates
San Diego, California, United States
APF Research, LLC
Miami, Florida, United States
International Research Associates, LLC
Miami, Florida, United States
University of Louisville
Louisville, Kentucky, United States
Delta Research Partners
Bastrop, Louisiana, United States
Start Date
March 9, 2022
Primary Completion Date
September 29, 2022
Completion Date
October 6, 2022
Last Updated
July 21, 2023
NCT06803589
NCT05229432
NCT03876288
NCT07287943
NCT07324785
NCT05880199
Lead Sponsor
Processa Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions